Actively Recruiting

Phase 2
Age: 18Years +
MALE
ID06849544

Phase II Trial to Investigate Safety and Efficacy of Four Dosing Regimens of OTL78 Injection (Zopocianine), a PSMA-Targeted Fluorescent Agent, for Intraoperative Imaging of Prostate Cancer

Led by Clinton Bahler · Updated on 2026-05-05

22

Participants Needed

3

Research Sites

4 weeks

Total Duration

On this page

Sponsors

C

Clinton Bahler

Lead Sponsor

I

Indiana University

Collaborating Sponsor

AI-Summary

What this Trial Is About

This trial investigates the use of Zopocianine (OTL78), a fluorescent drug that targets Prostate Specific Membrane Antigen (PSMA), to improve detection of cancerous tissue during prostate surgery. It focuses on men with biopsy-confirmed prostate cancer who are scheduled for prostate removal and lymph node dissection. The study aims to better visualize tumors and affected lymph nodes to potentially reduce leftover cancer and improve surgery outcomes. Participants receive one dose of Zopocianine at varying amounts (0.03 or 0.06 mg/kg) and timings before surgery, ranging from 1 hour to 7 days prior. The drug is used together with Near InfraRed (NIR) fluorescent imaging during surgery to help identify cancer tissue. Four different dosing schedules are compared to assess safety and how well each helps detect cancerous tissue during the operation. During the study, participants undergo standard surgery with added imaging using the study drug. Researchers monitor safety from screening through 6 weeks after surgery, tracking any significant events on the day of surgery. They also evaluate how well the drug detects primary and metastatic cancer and if the planned surgery is carried out as intended. Follow-up assessments and safety checks continue for several weeks after the procedure.

CONDITIONS

Brief Title

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent and HIPAA form
  • Male subjects 18 years or older
  • Diagnosed with primary prostate cancer Grade Group 3 to 5 (≥ cT3) or have suspected spread beyond prostate or lymph node involvement
  • Scheduled for standard robotic prostatectomy and lymph node dissection
  • Able to understand study requirements and comply with study procedures
  • Agree to use medically acceptable birth control or abstinence during the study and follow contraceptive guidelines for partners
Not Eligible

You will not qualify if you...

  • Surgery planned using an extraperitoneal approach
  • History of severe allergic reactions to indocyanine green
  • Allergy to any component of Zopocianine including DUPA, polyethylene glycol-dipeptide linker, or chlorodye
  • Impaired kidney (eGFR < 50 mL/min) or liver function (bilirubin > 2× normal or ALT/AST > 3× normal)
  • QTc interval ≥ 470 msec on ECG at screening
  • Significant acute or chronic illness that may affect safety or study completion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - From 2 to 7 days prior to day of surgery

Participants receive a single dose of ZOPOCIANINE at various times before surgery to assist with fluorescent imaging during prostatectomy and lymph node dissection.

1 dosing visit and 1 surgery visit

Follow-up

Duration - Up to 6 weeks after surgery

Participants are monitored for safety and tolerability of ZOPOCIANINE after surgery.

Approximately 3 follow-up visits

Trial Site Locations

Total: 3 locations

1

Indiana University Health North Hospital

Carmel, Indiana, United States, 46032

Actively Recruiting

2

Indiana University Health Methodist Hospital

Indianapolis, Indiana, United States, 46202

Actively Recruiting

3

Indiana University School of Medicine

Indianapolis, Indiana, United States, 46202

Actively Recruiting

Loading map...

Research Team

A

Ashley Frazee, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Similar Trials

Phase 1/2 Study of HLD-0915 in Patients With Metastatic Cast...

Prostate Cancer Metastatic Disease

Actively Recruiting

11 locations

Exploration of Treatment Effect of Novel Hormone Therapy Com...

Prostate Cancer Metastatic Disease

Actively Recruiting

1 location

Extended Pelvic Lymph Node Dissection vs. No Pelvic Lymph No...

Prostate Cancer Surgery

Actively Recruiting

15 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here